Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Published Date: 08 Sep 2025

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot